ClinicalTrials.gg
Active, not recruitingNCT07855250Updated Oct 21, 2026

An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 Inhibition

A Phase 1 interventional study of Rilzabrutinib and Rosuvastatin in Healthy Volunteer, sponsored by Sanofi. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Sanofi · Phase 1, Interventional, and Basic science

Updated Oct 21, 2026Now Active, not recruitingNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The study is a single-center, Phase-1, open-label, one-sequence, two-treatment period, cross-over, DDI study designed to investigate the effects of rilzabrutinib on the PK of digoxin (as P-gp substrate) and of rosuvastatin (as substrate of BCRP, OATP1B1, and OATP1B3) in healthy male and female participants. For this study a cocktail of digoxin and rosuvastatin will be used.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 55 years of age inclusive.
  • Body weight between 50.0 and 100.0 kg for males, 40.0 and 90.0 kg for females.
  • use by male and female participants should be consistent with local regulations

Exclusion criteria

Exclusion Criteria

  • History of serious infections requiring intravenous therapy.
  • Frequent headaches, migraine, nausea or vomiting.
  • Blood donation within 1 month before inclusion.
  • History of drug or allergic disease.
  • History of drug or alcohol abuse.
  • Smoking regularly more than 5 cigarettes or equivalent in nicotine per week
  • Excessive consumption of beverages containing xanthine bases.
  • Pregnancy or breastfeeding.
  • Recent vaccinations.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    Treatment A then Treatment B

    Treatment A in Period 1: digoxin + rosuvastatin cocktail alone on Day 1 of Period 1 Treatment B in Period 2: rilzabrutinib (SAR444671) BID from Day 1 to Day 12 of Period 2, plus digoxin + rosuvastatin cocktail on Day 8 of Period 2

    Drug: Rilzabrutinib · Drug: Rosuvastatin · Drug: Digoxin

Interventions

  • From Day 1 to Day 12 of Period 2

    Also known as: SAR444671

  • DrugRosuvastatin

    Single dose on Day 1 of Period 1 and on Day 8 of Period 2

    Also known as: Crestor

  • DrugDigoxin

    Single dose on Day 1 of Period 1 and on Day 8 of Period 2

    Also known as: Lanicor

06

What researchers measure

Primary outcomes

  1. AUC for digoxin and rosuvastatin

    area under curve

    Time frame: Up to Day 13 in Period 2

  2. AUClast for digoxin and rosuvastatin

    area under the curve from time zero to the last measurable concentration

    Time frame: Up to Day 13 in Period 2

  3. Cmax for digoxin and rosuvastatin

    maximum (peak) plasma concentration

    Time frame: Up to Day 13 in Period 2

Secondary outcomes

  1. tmax for digoxin and for rosuvastatin

    time to reach maximum plasma concentration

    Time frame: Up to Day 13 in Period 2

  2. tmax for rilzabrutinib

    time to reach maximum plasma concentration

    Time frame: Up to Day 11 in Period 2

  3. Cmax for rilzabrutinib

    maximum (peak) plasma concentration

    Time frame: Up to Day 11 in Period 2

  4. AUC0-tau for rilzabrutinib

    area under the plasma concentration-time curve from time 0 to tau

    Time frame: Up to Day 11 in Period 2

  5. Assessment of AEs and TEAEs

    including clinical laboratory evaluation, vital signs, and electrocardiogram (ECG).

    Time frame: Up to Day 21 in Period 2

07

Study locations

1 site
  • Investigational Site Number : 1240001
    Québec, Quebec G1P 0A2, Canada
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Nov 2026, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Oct 2, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Nov 3, 2026
CompletionEst.
Nov 3, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 21, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 3 updates
  1. Oct 21, 2026
    Recruiting→Active, not recruiting
    + 2 other changes: contact details and site details
  2. Oct 19, 2026
    Minor edits only
    + 2 other changes: verification date and date precision
  3. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855250
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Oct 1, 2026
Primary completion
Nov 3, 2026 (estimated)
Completion
Nov 3, 2026 (estimated)
Last update
Oct 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilzabrutinib

Start the discussion